Investigational Drug Information for Famitinib
What is the drug development status for Famitinib?
Famitinib is an investigational drug.
There have been 59 clinical trials for Famitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 20th 2023.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.
There are one hundred and thirty-two US patents protecting this investigational drug and three hundred and eleven international patents.
Summary for Famitinib
| US Patents | 132 |
| International Patents | 311 |
| US Patent Applications | 328 |
| WIPO Patent Applications | 108 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2023-08-20) |
| Vendors | 21 |
Recent Clinical Trials for Famitinib
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer | Qinglei Gao | PHASE2 |
| A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PHASE2 |
| Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. | Fudan University | PHASE2 |
Clinical Trial Summary for Famitinib
Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib
US Patents for Famitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Famitinib | ⤷ Start Trial | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis | Genentech, Inc. (South San Francisco, CA) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Methods of treatment of malignancies | Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Famitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Famitinib | European Patent Office | EP3344624 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Hong Kong | HK1256997 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2018532706 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2019172690 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2021130712 | 2035-09-02 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
